nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2C19—Prednisone—psoriatic arthritis	0.101	0.117	CbGbCtD
Carbinoxamine—CYP2E1—Dexamethasone—psoriatic arthritis	0.1	0.116	CbGbCtD
Carbinoxamine—CYP2B6—Dexamethasone—psoriatic arthritis	0.0988	0.115	CbGbCtD
Carbinoxamine—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0802	0.0932	CbGbCtD
Carbinoxamine—CYP2C8—Dexamethasone—psoriatic arthritis	0.0748	0.0869	CbGbCtD
Carbinoxamine—CYP2C19—Dexamethasone—psoriatic arthritis	0.0628	0.0729	CbGbCtD
Carbinoxamine—CYP3A4—Triamcinolone—psoriatic arthritis	0.0608	0.0706	CbGbCtD
Carbinoxamine—CYP2C9—Dexamethasone—psoriatic arthritis	0.0522	0.0606	CbGbCtD
Carbinoxamine—CYP3A4—Betamethasone—psoriatic arthritis	0.0522	0.0606	CbGbCtD
Carbinoxamine—CYP3A4—Prednisolone—psoriatic arthritis	0.0515	0.0598	CbGbCtD
Carbinoxamine—CYP3A4—Prednisone—psoriatic arthritis	0.0486	0.0565	CbGbCtD
Carbinoxamine—CYP2D6—Dexamethasone—psoriatic arthritis	0.0477	0.0554	CbGbCtD
Carbinoxamine—CYP3A4—Dexamethasone—psoriatic arthritis	0.0303	0.0353	CbGbCtD
Carbinoxamine—Neuropathy peripheral—Auranofin—psoriatic arthritis	0.00361	0.0259	CcSEcCtD
Carbinoxamine—Agranulocytosis—Auranofin—psoriatic arthritis	0.00344	0.0246	CcSEcCtD
Carbinoxamine—Neuritis—Prednisolone—psoriatic arthritis	0.00281	0.0202	CcSEcCtD
Carbinoxamine—Neuritis—Triamcinolone—psoriatic arthritis	0.00259	0.0185	CcSEcCtD
Carbinoxamine—Neuritis—Methylprednisolone—psoriatic arthritis	0.00258	0.0185	CcSEcCtD
Carbinoxamine—Neuritis—Dexamethasone—psoriatic arthritis	0.00235	0.0168	CcSEcCtD
Carbinoxamine—Neuritis—Betamethasone—psoriatic arthritis	0.00235	0.0168	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Auranofin—psoriatic arthritis	0.0023	0.0165	CcSEcCtD
Carbinoxamine—Anorexia—Auranofin—psoriatic arthritis	0.00224	0.0161	CcSEcCtD
Carbinoxamine—Dyspepsia—Auranofin—psoriatic arthritis	0.00207	0.0148	CcSEcCtD
Carbinoxamine—Neuritis—Prednisone—psoriatic arthritis	0.00204	0.0147	CcSEcCtD
Carbinoxamine—Decreased appetite—Auranofin—psoriatic arthritis	0.00204	0.0146	CcSEcCtD
Carbinoxamine—Constipation—Auranofin—psoriatic arthritis	0.00201	0.0144	CcSEcCtD
Carbinoxamine—Wheezing—Triamcinolone—psoriatic arthritis	0.00187	0.0134	CcSEcCtD
Carbinoxamine—Urticaria—Auranofin—psoriatic arthritis	0.00187	0.0134	CcSEcCtD
Carbinoxamine—Euphoric mood—Prednisolone—psoriatic arthritis	0.0018	0.0129	CcSEcCtD
Carbinoxamine—Euphoric mood—Triamcinolone—psoriatic arthritis	0.00166	0.0119	CcSEcCtD
Carbinoxamine—Euphoric mood—Methylprednisolone—psoriatic arthritis	0.00165	0.0119	CcSEcCtD
Carbinoxamine—Diarrhoea—Auranofin—psoriatic arthritis	0.00161	0.0115	CcSEcCtD
Carbinoxamine—Euphoric mood—Dexamethasone—psoriatic arthritis	0.0015	0.0108	CcSEcCtD
Carbinoxamine—Euphoric mood—Betamethasone—psoriatic arthritis	0.0015	0.0108	CcSEcCtD
Carbinoxamine—Vomiting—Auranofin—psoriatic arthritis	0.00149	0.0107	CcSEcCtD
Carbinoxamine—Nausea—Auranofin—psoriatic arthritis	0.0014	0.01	CcSEcCtD
Carbinoxamine—Irritability—Methylprednisolone—psoriatic arthritis	0.00133	0.00957	CcSEcCtD
Carbinoxamine—Euphoric mood—Prednisone—psoriatic arthritis	0.00131	0.0094	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisolone—psoriatic arthritis	0.00128	0.0092	CcSEcCtD
Carbinoxamine—Irritability—Dexamethasone—psoriatic arthritis	0.00121	0.0087	CcSEcCtD
Carbinoxamine—Irritability—Betamethasone—psoriatic arthritis	0.00121	0.0087	CcSEcCtD
Carbinoxamine—Sweating increased—Triamcinolone—psoriatic arthritis	0.00118	0.00846	CcSEcCtD
Carbinoxamine—Sweating increased—Methylprednisolone—psoriatic arthritis	0.00118	0.00844	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.00115	0.00825	CcSEcCtD
Carbinoxamine—Sweating increased—Betamethasone—psoriatic arthritis	0.00107	0.00768	CcSEcCtD
Carbinoxamine—Sweating increased—Dexamethasone—psoriatic arthritis	0.00107	0.00768	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.00106	0.00759	CcSEcCtD
Carbinoxamine—Irritability—Prednisone—psoriatic arthritis	0.00106	0.00758	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.00106	0.00757	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—psoriatic arthritis	0.00105	0.00756	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.00096	0.00689	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.00096	0.00689	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisone—psoriatic arthritis	0.000932	0.00669	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—psoriatic arthritis	0.000883	0.00633	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisolone—psoriatic arthritis	0.000865	0.0062	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000836	0.006	CcSEcCtD
Carbinoxamine—Vertigo—Prednisolone—psoriatic arthritis	0.000824	0.00591	CcSEcCtD
Carbinoxamine—Convulsion—Prednisolone—psoriatic arthritis	0.000795	0.0057	CcSEcCtD
Carbinoxamine—Vertigo—Triamcinolone—psoriatic arthritis	0.000758	0.00544	CcSEcCtD
Carbinoxamine—Vertigo—Methylprednisolone—psoriatic arthritis	0.000757	0.00543	CcSEcCtD
Carbinoxamine—Convulsion—Triamcinolone—psoriatic arthritis	0.000731	0.00524	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisolone—psoriatic arthritis	0.000731	0.00524	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.00073	0.00524	CcSEcCtD
Carbinoxamine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00073	0.00523	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000724	0.00519	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—psoriatic arthritis	0.000713	0.00511	CcSEcCtD
Carbinoxamine—Confusional state—Methylprednisolone—psoriatic arthritis	0.000693	0.00497	CcSEcCtD
Carbinoxamine—Vertigo—Dexamethasone—psoriatic arthritis	0.000688	0.00493	CcSEcCtD
Carbinoxamine—Vertigo—Betamethasone—psoriatic arthritis	0.000688	0.00493	CcSEcCtD
Carbinoxamine—Insomnia—Prednisolone—psoriatic arthritis	0.000677	0.00486	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisolone—psoriatic arthritis	0.000673	0.00482	CcSEcCtD
Carbinoxamine—Tachycardia—Triamcinolone—psoriatic arthritis	0.000672	0.00482	CcSEcCtD
Carbinoxamine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000671	0.00481	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000666	0.00477	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000666	0.00477	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000664	0.00476	CcSEcCtD
Carbinoxamine—Convulsion—Betamethasone—psoriatic arthritis	0.000663	0.00476	CcSEcCtD
Carbinoxamine—Convulsion—Dexamethasone—psoriatic arthritis	0.000663	0.00476	CcSEcCtD
Carbinoxamine—Hypotension—Methylprednisolone—psoriatic arthritis	0.000642	0.0046	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisone—psoriatic arthritis	0.000628	0.00451	CcSEcCtD
Carbinoxamine—Insomnia—Triamcinolone—psoriatic arthritis	0.000623	0.00447	CcSEcCtD
Carbinoxamine—Insomnia—Methylprednisolone—psoriatic arthritis	0.000622	0.00446	CcSEcCtD
Carbinoxamine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000618	0.00443	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000617	0.00443	CcSEcCtD
Carbinoxamine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000617	0.00443	CcSEcCtD
Carbinoxamine—Agitation—Prednisone—psoriatic arthritis	0.000613	0.00439	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000612	0.00439	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000612	0.00439	CcSEcCtD
Carbinoxamine—Tachycardia—Betamethasone—psoriatic arthritis	0.00061	0.00437	CcSEcCtD
Carbinoxamine—Tachycardia—Dexamethasone—psoriatic arthritis	0.00061	0.00437	CcSEcCtD
Carbinoxamine—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000606	0.00435	CcSEcCtD
Carbinoxamine—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000605	0.00434	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000604	0.00433	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000604	0.00433	CcSEcCtD
Carbinoxamine—Vertigo—Prednisone—psoriatic arthritis	0.000599	0.0043	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—psoriatic arthritis	0.000597	0.00428	CcSEcCtD
Carbinoxamine—Anorexia—Dexamethasone—psoriatic arthritis	0.000596	0.00427	CcSEcCtD
Carbinoxamine—Anorexia—Betamethasone—psoriatic arthritis	0.000596	0.00427	CcSEcCtD
Carbinoxamine—Urticaria—Prednisolone—psoriatic arthritis	0.000595	0.00427	CcSEcCtD
Carbinoxamine—Fatigue—Triamcinolone—psoriatic arthritis	0.000594	0.00426	CcSEcCtD
Carbinoxamine—Fatigue—Methylprednisolone—psoriatic arthritis	0.000592	0.00425	CcSEcCtD
Carbinoxamine—Hypotension—Dexamethasone—psoriatic arthritis	0.000584	0.00419	CcSEcCtD
Carbinoxamine—Hypotension—Betamethasone—psoriatic arthritis	0.000584	0.00419	CcSEcCtD
Carbinoxamine—Convulsion—Prednisone—psoriatic arthritis	0.000578	0.00414	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—psoriatic arthritis	0.000574	0.00412	CcSEcCtD
Carbinoxamine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000568	0.00407	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000566	0.00406	CcSEcCtD
Carbinoxamine—Insomnia—Betamethasone—psoriatic arthritis	0.000565	0.00405	CcSEcCtD
Carbinoxamine—Insomnia—Dexamethasone—psoriatic arthritis	0.000565	0.00405	CcSEcCtD
Carbinoxamine—Paraesthesia—Betamethasone—psoriatic arthritis	0.000561	0.00402	CcSEcCtD
Carbinoxamine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000561	0.00402	CcSEcCtD
Carbinoxamine—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00055	0.00394	CcSEcCtD
Carbinoxamine—Dyspepsia—Betamethasone—psoriatic arthritis	0.00055	0.00394	CcSEcCtD
Carbinoxamine—Urticaria—Triamcinolone—psoriatic arthritis	0.000547	0.00392	CcSEcCtD
Carbinoxamine—Urticaria—Methylprednisolone—psoriatic arthritis	0.000546	0.00391	CcSEcCtD
Carbinoxamine—Decreased appetite—Betamethasone—psoriatic arthritis	0.000543	0.0039	CcSEcCtD
Carbinoxamine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000543	0.0039	CcSEcCtD
Carbinoxamine—Fatigue—Betamethasone—psoriatic arthritis	0.000539	0.00386	CcSEcCtD
Carbinoxamine—Fatigue—Dexamethasone—psoriatic arthritis	0.000539	0.00386	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisone—psoriatic arthritis	0.000531	0.00381	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000526	0.00377	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—psoriatic arthritis	0.000525	0.00377	CcSEcCtD
Carbinoxamine—Anorexia—Prednisone—psoriatic arthritis	0.000519	0.00372	CcSEcCtD
Carbinoxamine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000515	0.00369	CcSEcCtD
Carbinoxamine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000515	0.00369	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—psoriatic arthritis	0.000501	0.00359	CcSEcCtD
Carbinoxamine—Urticaria—Betamethasone—psoriatic arthritis	0.000496	0.00356	CcSEcCtD
Carbinoxamine—Urticaria—Dexamethasone—psoriatic arthritis	0.000496	0.00356	CcSEcCtD
Carbinoxamine—Dizziness—Prednisolone—psoriatic arthritis	0.000495	0.00355	CcSEcCtD
Carbinoxamine—Asthenia—Triamcinolone—psoriatic arthritis	0.000494	0.00354	CcSEcCtD
Carbinoxamine—Asthenia—Methylprednisolone—psoriatic arthritis	0.000493	0.00354	CcSEcCtD
Carbinoxamine—Insomnia—Prednisone—psoriatic arthritis	0.000492	0.00353	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisone—psoriatic arthritis	0.000489	0.0035	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—psoriatic arthritis	0.000483	0.00346	CcSEcCtD
Carbinoxamine—Dyspepsia—Prednisone—psoriatic arthritis	0.000479	0.00344	CcSEcCtD
Carbinoxamine—Decreased appetite—Prednisone—psoriatic arthritis	0.000473	0.00339	CcSEcCtD
Carbinoxamine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00047	0.00337	CcSEcCtD
Carbinoxamine—Fatigue—Prednisone—psoriatic arthritis	0.000469	0.00336	CcSEcCtD
Carbinoxamine—Headache—Prednisolone—psoriatic arthritis	0.000469	0.00336	CcSEcCtD
Carbinoxamine—Constipation—Prednisone—psoriatic arthritis	0.000465	0.00334	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—psoriatic arthritis	0.000459	0.00329	CcSEcCtD
Carbinoxamine—Dizziness—Triamcinolone—psoriatic arthritis	0.000455	0.00327	CcSEcCtD
Carbinoxamine—Dizziness—Methylprednisolone—psoriatic arthritis	0.000454	0.00326	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisone—psoriatic arthritis	0.000448	0.00322	CcSEcCtD
Carbinoxamine—Asthenia—Dexamethasone—psoriatic arthritis	0.000448	0.00322	CcSEcCtD
Carbinoxamine—Asthenia—Betamethasone—psoriatic arthritis	0.000448	0.00322	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000445	0.00319	CcSEcCtD
Carbinoxamine—Nausea—Prednisolone—psoriatic arthritis	0.000445	0.00319	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00044	0.00315	CcSEcCtD
Carbinoxamine—Vomiting—Triamcinolone—psoriatic arthritis	0.000438	0.00314	CcSEcCtD
Carbinoxamine—Vomiting—Methylprednisolone—psoriatic arthritis	0.000437	0.00313	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—psoriatic arthritis	0.000434	0.00311	CcSEcCtD
Carbinoxamine—Urticaria—Prednisone—psoriatic arthritis	0.000432	0.0031	CcSEcCtD
Carbinoxamine—Headache—Triamcinolone—psoriatic arthritis	0.000431	0.00309	CcSEcCtD
Carbinoxamine—Headache—Methylprednisolone—psoriatic arthritis	0.000431	0.00309	CcSEcCtD
Carbinoxamine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000428	0.00307	CcSEcCtD
Carbinoxamine—Diarrhoea—Betamethasone—psoriatic arthritis	0.000428	0.00307	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—psoriatic arthritis	0.000425	0.00305	CcSEcCtD
Carbinoxamine—Dizziness—Betamethasone—psoriatic arthritis	0.000413	0.00296	CcSEcCtD
Carbinoxamine—Dizziness—Dexamethasone—psoriatic arthritis	0.000413	0.00296	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—psoriatic arthritis	0.000411	0.00295	CcSEcCtD
Carbinoxamine—Nausea—Triamcinolone—psoriatic arthritis	0.000409	0.00293	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—psoriatic arthritis	0.000408	0.00293	CcSEcCtD
Carbinoxamine—Nausea—Methylprednisolone—psoriatic arthritis	0.000408	0.00293	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—psoriatic arthritis	0.000404	0.0029	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—psoriatic arthritis	0.0004	0.00287	CcSEcCtD
Carbinoxamine—Vomiting—Dexamethasone—psoriatic arthritis	0.000397	0.00285	CcSEcCtD
Carbinoxamine—Vomiting—Betamethasone—psoriatic arthritis	0.000397	0.00285	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—psoriatic arthritis	0.000395	0.00284	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—psoriatic arthritis	0.000392	0.00281	CcSEcCtD
Carbinoxamine—Headache—Betamethasone—psoriatic arthritis	0.000391	0.00281	CcSEcCtD
Carbinoxamine—Headache—Dexamethasone—psoriatic arthritis	0.000391	0.00281	CcSEcCtD
Carbinoxamine—Asthenia—Prednisone—psoriatic arthritis	0.00039	0.0028	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000375	0.00269	CcSEcCtD
Carbinoxamine—Diarrhoea—Prednisone—psoriatic arthritis	0.000372	0.00267	CcSEcCtD
Carbinoxamine—Nausea—Betamethasone—psoriatic arthritis	0.000371	0.00266	CcSEcCtD
Carbinoxamine—Nausea—Dexamethasone—psoriatic arthritis	0.000371	0.00266	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—psoriatic arthritis	0.000361	0.00259	CcSEcCtD
Carbinoxamine—Dizziness—Prednisone—psoriatic arthritis	0.00036	0.00258	CcSEcCtD
Carbinoxamine—Vomiting—Prednisone—psoriatic arthritis	0.000346	0.00248	CcSEcCtD
Carbinoxamine—Headache—Prednisone—psoriatic arthritis	0.000341	0.00244	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—psoriatic arthritis	0.000326	0.00234	CcSEcCtD
Carbinoxamine—Nausea—Prednisone—psoriatic arthritis	0.000323	0.00232	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—psoriatic arthritis	0.000311	0.00223	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—psoriatic arthritis	0.000301	0.00216	CcSEcCtD
Carbinoxamine—Vomiting—Methotrexate—psoriatic arthritis	0.000289	0.00207	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—psoriatic arthritis	0.000285	0.00204	CcSEcCtD
Carbinoxamine—Nausea—Methotrexate—psoriatic arthritis	0.00027	0.00194	CcSEcCtD
